Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
Study evaluating the pharmacokinetics, safety and tolerability of Voriconazole in children aged 2-12 years who require treatment of systemic fungal infection
To investigate the pharmacokinetics of voriconazole following multiple dosing with intravenous voriconazole in children aged 2 to less than (<)12 years.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
MAJ Il y a 4 ans
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME)
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 4 ans
AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
Compare the progression-free survival (PFS) of treatment-naïve patients with mRCC receiving AG-013736 vs sorafenib. Estimate the progression-free survival (PFS) of previously-treated Asian patien...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A Study to Determine the Body's Immune Response To a Vaccination for Herpes Zoster In Subjects Who Have Rheumatoid Arthritis and Receive Tofacitinib (CP-690,550) (the drug being tested) or Placebo
To evaluate the effect of tofacitinib on varicella-zoster virus (VZV)-specific immunoglobulin responses in subjects with RA on background methotrexate therapy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
• To compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus etanercept (50 mg BIW) and placebo for the reduction in severity of plaque psoriasis after 12 weeks of treatment in subjects wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
1. To compare the efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo for the treatment of rheumatological signs and symptoms of PsA, in subjects with active PsA who have had an ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
To compare the time from randomization to treatment failure over a five year period for subjects treated with celecoxib versus subjects treated with placebo, where treatment failure is defined as the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
The primary objective of this study is to evaluate the long-term safety of sitaxsentan and sitaxsentan plus sildenafil in subjects with PAH who are eligible for this study if B1321003 (combination the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN RANDOMIZOVANÉ, MULTICENTRICKÉ, DVOJITĚ ZASLEPENÉ KLINICKÉ HODNOCENÍ FÁZE 2 POROVNÁNÍ PALBOCICLIBU V KOMBINACI S CETUXIMABEM PROTI CETUXIMABU K LÉČBĚ PACIENTŮ S RECIDIVUJÍCÍM NEBO METASTAZUJÍCÍM DLAŽDICOVÝM KARCINOMEM HLAVY A KRKU, S NEGATIVNÍM LIDSKÝM PAPILOMAVIREM, BEZ PŘEDCHOZÍ LÉČBY CETUXIMABEM, PO SELHÁNÍ JEDNÉ PŘEDCHOZÍ LÉČBY CHEMOTERAPIÍ NA BÁZI PLATINY
To demonstrate that the combination of palbociclib with cetuximab is superior to cetuximab in prolonging Overall Survival in HPV-negative, cetuximab-naïve patients with Recurrent/Metastatic Squamous C...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A 12-MONTH OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES
To evaluate the long term safety and tolerability of pregabalin in pediatric patients 1 month through 16 years of age with partial onset seizures.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
9
10
11
12
13
14
15
16
17
18
Suivant